MediWound Ltd. (NASDAQ:MDWD) received a $10.00 price objective from research analysts at Jefferies Group LLC in a research note issued to investors on Friday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective points to a potential upside of 61.14% from the company’s current price.
MDWD has been the topic of a number of other research reports. SunTrust Banks, Inc. reissued a “buy” rating on shares of MediWound in a research note on Monday, June 26th. Zacks Investment Research lowered MediWound from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Oppenheimer Holdings, Inc. set a $10.00 price objective on MediWound and gave the stock a “buy” rating in a research note on Monday, May 8th. Finally, Aegis reissued a “buy” rating and set a $11.00 price objective on shares of MediWound in a research note on Thursday, May 25th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $9.19.
MediWound (NASDAQ:MDWD) opened at 6.2056 on Friday. The stock’s market capitalization is $136.24 million. MediWound has a 1-year low of $4.25 and a 1-year high of $8.58. The firm’s 50 day moving average is $6.66 and its 200 day moving average is $6.52.
MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.01. The company had revenue of $0.69 million for the quarter, compared to analyst estimates of $0.69 million. MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. The business’s quarterly revenue was up 93.8% on a year-over-year basis. During the same period last year, the firm posted ($0.34) EPS. On average, equities research analysts anticipate that MediWound will post ($0.77) earnings per share for the current year.
A number of institutional investors have recently added to or reduced their stakes in MDWD. Renaissance Technologies LLC raised its position in MediWound by 11.9% in the fourth quarter. Renaissance Technologies LLC now owns 74,300 shares of the biopharmaceutical company’s stock worth $340,000 after buying an additional 7,900 shares during the period. Wells Fargo & Company MN increased its stake in MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 8,745 shares in the last quarter. Wellington Management Group LLP increased its stake in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after buying an additional 213,745 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. increased its stake in MediWound by 20.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock worth $13,791,000 after buying an additional 342,165 shares in the last quarter. 27.32% of the stock is currently owned by institutional investors.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
